Talk Bio

Summit Therapeutics has highlighted updated data from its global Phase III HARMONi trial for ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, in patients with EGFR-mutated advanced non-squamous non-small cell lung cancer treated with prior third-generation EGFR TKIs. The latest analysis, with a June 2026 data cutoff, shows a consistent overall survival benefit for Western patients treated with ivonescimab plus platinum-doublet chemotherapy versus chemotherapy alone, with a hazard ratio of 0.76 in both the full intention-to-treat population and the Western subgroup. Western patients had a median follow-up of 23.2 months in this updated analysis, bringing their survival performance into alignment with the previously reported OS benefit in Asian patients, who had longer follow-up at earlier analyses. Median overall survival was 16.8 months for ivonescimab plus chemotherapy versus 14.0 months for placebo plus chemotherapy at the primary analysis, a trend that tightened an...